Take heed to this text |
![Quantum Surgical makes its first surgical robotic sale within the U.S. Quantum Surgical makes its first surgical robotic sale within the U.S.](https://www.therobotreport.com/wp-content/uploads/2023/12/Quantum-Surgical-Epione-3D-web-768x499-1.webp)
The Epione surgical robotic system. | Supply: Quantum Surgical
Surgical robots are more and more in a position to attain areas and deal with circumstances that had been beforehand inconceivable. Quantum Surgical SAS mentioned it has made the primary sale of its Epione surgical robotic platform within the U.S. Epione is designed to deal with inoperable tumors within the stomach, together with the liver, kidney, and pancreas.
“Your complete Quantum Surgical crew is thrilled about this primary acquisition in the US,” mentioned Bertin Nahum, co-founder and president of Quantum Surgical, in a launch. “Affected person therapy and buyer satisfaction are our priorities, and we’re very happy with the optimistic suggestions we’ve acquired from our customers, which can assist speed up Epione’s adoption within the U.S. territory.”
Based in 2017, Quantum Surgical mentioned the Epione robotic percutaneous ablation platform is devoted to the healing and early therapy of cancers. By standardizing entry to care, extra sufferers can profit from progressive, higher focused, and fewer invasive remedies, asserted the Montpellier, France-based firm.
Epione designed to deal with inoperable tumors
Epione makes use of a robotic arm, a navigation system, and a digital camera. The system inserts a needle by the pores and skin to the tumor and destroys it.
The system allows the early and minimally invasive therapy of stomach tumors, the corporate mentioned. The surgical robotic permits clinicians to deal with inoperable tumors, together with these which might be troublesome to achieve due to their to dimension or location.
Surgeons have already used Epione to deal with greater than 300 sufferers worldwide, mentioned Quantum Surgical. The firm received the Prix Galien USA in 2022, which it mentioned is equal to the Nobel Prize for biopharmaceutical analysis.
This 12 months, it joined French Tech 2030, a authorities program supposed to encourage innovation in that nation.
Miami middle dwelling of first Quantum Surgical U.S. unit
Widespread Gear Finance, a pacesetter in tools financing that does enterprise as K2 Capital Group, acquired its first Epione robotic within the U.S. It really works with healthcare organizations throughout the U.S., together with the Miami Cardiac & Vascular Institute, a most cancers middle that used Epione in Might 2023.
That most cancers middle has now entered right into a lease with K2 for the Epione system, Quantum Surgical introduced final week.
Epione just lately acquired clearance to deal with lung circumstances along with the liver, kidney, and pancreas. The system is CE-marked for Europe for stomach and lung tumors, and the U.S. Meals and Drug Administration (FDA) has granted clearance for stomach tumors.
The worldwide marketplace for surgical robotics might expertise a compound annual progress charge of 15.7% from $6.2 billion in 2022 to $25.7 billion by 2032, in accordance with Market.us. The analysis agency mentioned the North American market had the biggest share at 51% in 2022.
Equally, Priority Analysis predicted a 16.4% CAGR, from $8 billion in 2022 to $36.37 billion by 2032, and it additionally cited the North American market. Maximize Market Analysis Pvt. Ltd. mentioned that demand and growing capabilities will assist serve North American, Asia-Pacific, and international demand, as income grows from $71.94 billion in 2022 to $124.18 billion by 2029 at 8.11%.
Editor’s observe: This text was syndicated from MassDevice, a sibling web site to The Robotic Report.